|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cymabay Therapeutics, Inc. (CBAY) |
|
|
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
114,780,000 |
| Market
Cap: |
3.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.47 - $32.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
51,301 |
| Total Buy Value |
$0 |
$0 |
$0 |
$100,037 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
6,000 |
235,302 |
552,511 |
672,611 |
| Total Sell Value |
$191,849 |
$4,692,766 |
$8,944,114 |
$10,085,429 |
| Total People Sold |
1 |
5 |
6 |
7 |
| Total Sell Transactions |
1 |
14 |
33 |
36 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcwherter Charles |
President of R&D |
• – – |
2023-06-20 |
4 |
OE |
$5.00 |
$108,745 |
D/D |
21,749 |
36,749 |
|
- |
|
| Mcwherter Charles |
President of R&D |
• – – |
2023-05-18 |
4 |
AS |
$9.08 |
$197,387 |
D/D |
(21,749) |
15,000 |
|
67% |
|
| Mcwherter Charles |
President of R&D |
• – – |
2023-05-18 |
4 |
OE |
$5.00 |
$108,745 |
D/D |
21,749 |
36,749 |
|
- |
|
| Quinlan Paul T |
General Counsel |
• – – |
2023-05-15 |
4 |
AS |
$10.37 |
$51,831 |
D/D |
(5,000) |
0 |
|
41% |
|
| Quinlan Paul T |
General Counsel |
• – – |
2023-05-15 |
4 |
OE |
$2.94 |
$14,700 |
D/D |
5,000 |
5,000 |
|
- |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-04-17 |
4 |
S |
$9.54 |
$1,070,536 |
D/D |
(112,219) |
20,000 |
|
-36% |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-04-17 |
4 |
OE |
$4.37 |
$490,397 |
D/D |
112,219 |
132,219 |
|
- |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-04-13 |
4 |
S |
$8.98 |
$69,880 |
D/D |
(7,781) |
20,000 |
|
-46% |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-04-13 |
4 |
OE |
$4.37 |
$34,003 |
D/D |
7,781 |
27,781 |
|
- |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-03-28 |
4 |
S |
$8.99 |
$899 |
D/D |
(100) |
20,000 |
|
-38% |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2023-03-28 |
4 |
OE |
$4.37 |
$437 |
D/D |
100 |
20,100 |
|
- |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2022-06-06 |
4 |
B |
$1.95 |
$100,037 |
D/D |
51,301 |
171,301 |
2.81 |
70% |
|
| Kim Dennis D |
Chief Medical Officer |
• – – |
2022-01-19 |
4 |
B |
$3.04 |
$60,800 |
D/D |
20,000 |
20,000 |
2.74 |
-31% |
|
| Stuart Lewis J |
Chief Commercial OfficerOffice |
• – – |
2021-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
-3% |
|
| Aghazadeh Behzad |
10% Owner |
– – • |
2020-08-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,300,000 |
|
47% |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2019-10-10 |
4 |
B |
$4.30 |
$21,500 |
D/D |
5,000 |
120,000 |
2.81 |
- |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2019-09-23 |
4 |
B |
$5.55 |
$17,205 |
D/D |
3,100 |
115,000 |
2.81 |
- |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2019-09-20 |
4 |
B |
$5.50 |
$10,450 |
D/D |
1,900 |
111,900 |
2.81 |
- |
|
| Goldfischer Carl |
Director |
– • – |
2019-02-07 |
4 |
S |
$9.02 |
$105,328 |
D/D |
(11,675) |
0 |
|
- |
|
| Goldfischer Carl |
Director |
– • – |
2019-02-07 |
4 |
OE |
$5.00 |
$63,045 |
D/D |
11,675 |
11,675 |
|
- |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2018-12-21 |
4 |
B |
$6.54 |
$65,399 |
D/D |
10,000 |
110,000 |
2.81 |
- |
|
| Emster Kurt Von |
Director |
– • – |
2018-12-18 |
4 |
S |
$7.43 |
$397,365 |
I/I |
(53,492) |
131,036 |
|
- |
|
| Emster Kurt Von |
Director |
– • – |
2018-12-17 |
4 |
S |
$8.17 |
$726,223 |
I/I |
(88,889) |
184,528 |
|
- |
|
| Shah Sujal |
Chief Executive Officer |
• • – |
2018-10-15 |
4 |
B |
$9.90 |
$49,500 |
D/D |
5,000 |
100,000 |
2.81 |
- |
|
| Menold Daniel |
Vice President, Finance |
• – – |
2018-08-29 |
4 |
AS |
$13.00 |
$65,000 |
D/D |
(5,000) |
0 |
|
- |
|
165 Records found
|
|
Page 4 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
